<?xml version="1.0" ?>
<text author="Hung-Jun Lin, Weu Wang, Yi-You Huang, Wei-Tsen Liao, Ting-Yu Lin, Shyr-Yi Lin, Der-Zen Liu" dateCollected="2019-11-03" id="autogum_academic_doc057" shortTile="decellularized-lymph" sourceURL="https://www.mdpi.com/1999-4923/11/11/553/htm" speakerCount="0" speakerList="none" title="Decellularized Lymph Node Scaffolding as a Carrier for Dendritic Cells to Induce Anti-Tumor Immunity" type="academic">
<head>
<s type="frag">
1.	LS	@ord@
</s>
<s type="frag">
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Cancer	NNP	Cancer
is	VBZ	be
a	DT	a
major	JJ	major
cause	NN	cause
of	IN	of
human	JJ	human
death	NN	death
worldwide	RB	worldwide
.	.	.
</s>
<s type="decl">
Most	JJS	most
cancer	NN	cancer
patients	NNS	patient
receive	VBP	receive
chemotherapy	NN	chemotherapy
and	CC	and
radiation	NN	radiation
therapy	NN	therapy
,	,	,
they	PRP	they
are	VBP	be
often	RB	often
only	RB	only
partially	RB	partially
effective	JJ	effective
and	CC	and
lead	VB	lead
to	TO	to
a	DT	a
variety	NN	variety
of	IN	of
serious	JJ	serious
side	NN	side
effects	NNS	effect
.	.	.
</s>
<s type="decl">
In	IN	in
recent	JJ	recent
decades	NNS	decade
,	,	,
cancer	NN	cancer
immunotherapy	NN	immunotherapy
has	VBZ	have
been	VBN	be
validated	VBN	validate
as	IN	as
stimulating	VBG	stimulate
patients	NNS	patient
’	POS	&apos;s
own	JJ	own
immune	NN	immune
systems	NNS	system
to	TO	to
eliminate	VB	eliminate
cancers	NNS	cancer
.	.	.
</s>
<s type="sub">
Compared	VBN	compared
to	TO	to
chemotherapy	NN	chemotherapy
and	CC	and
radiation	NN	radiation
therapy	NN	therapy
,	,	,
cancer	NN	cancer
immunotherapy	NN	immunotherapy
can	MD	can
specifically	RB	specifically
target	VB	target
tumor	NN	tumor
cells	NNS	cell
by	IN	by
modulating	VBG	modulate
immune	NN	immune
cells	NNS	cell
without	IN	without
damage	NN	damage
to	TO	to
normal	JJ	normal
cells	NNS	cell
.	.	.
</s>
</p>
<p>
<s type="decl">
A	DT	a
variety	NN	variety
of	IN	of
cancer	NN	cancer
immunotherapies	NNS	immunotherapy
,	,	,
including	VBG	include
DC-based	VBN	DC-based
cancer	NN	cancer
vaccines	NNS	vaccine
,	,	,
chimeric	NN	chimeric
antigen	NN	antigen
receptor-T	NN	receptor-T
lymphocyte	NN	lymphocyte
therapies	NNS	therapy
,	,	,
immune	JJ	immune
checkpoint	NN	checkpoint
blockade	NN	blockade
antibody	NN	antibody
therapies	NNS	therapy
,	,	,
oncolytic	JJ	oncolytic
vaccine	NN	vaccine
,	,	,
and	CC	and
cytokines	NNS	cytokine
therapies	NNS	therapy
,	,	,
have	VBP	have
been	VBN	be
developed	VBN	develop
to	TO	to
induce	VB	induce
tumor-specific	JJ	tumor-specific
and	CC	and
cytotoxic	NN	cytotoxic
T	NN	T
lymphocyte	NN	lymphocyte
immune	NN	immune
responses	NNS	response
.	.	.
</s>
<s type="decl">
Dendritic	JJ	Dendritic
cell	NN	cell
based	VBN	base
therapies	NNS	therapy
have	VBP	have
been	VBN	be
widely	RB	widely
investigated	VBN	investigate
because	IN	because
dendritic	JJ	dendritic
cells	NNS	cell
(	-LRB-	(
DCs	NNS	DC
)	-RRB-	)
are	VBP	be
thought	VBN	think
to	TO	to
be	VB	be
the	DT	the
initiator	NN	initiator
in	IN	in
modulating	VBG	modulate
immunity	NN	immunity
.	.	.
</s>
<s type="decl">
DCs	NNS	DC
are	VBP	be
known	VBN	know
as	IN	as
professional	JJ	professional
antigen-presenting	JJ	antigen-presenting
cells	NNS	cell
,	,	,
responsible	JJ	responsible
for	IN	for
swallowing	VBG	swallow
tumor-associated	VBN	tumor-associated
antigens	NNS	antigen
,	,	,
presenting	VBG	present
them	PRP	them
to	TO	to
T	NNP	T
lymphocytes	NNS	lymphocyte
,	,	,
and	CC	and
inducing	VBG	induce
antigen-specific	JJ	antigen-specific
immune	NN	immune
responses	NNS	response
.	.	.
</s>
<s type="decl">
When	WRB	when
DCs	NNPS	DC
mature	VBP	mature
and	CC	and
become	VBP	become
activated	VBN	activate
,	,	,
they	PRP	they
will	MD	will
swallow	VB	swallow
the	DT	the
foreign	JJ	foreign
substances	NNS	substance
and	CC	and
subsequently	RB	subsequently
present	VB	present
the	DT	the
antigenic	JJ	antigenic
epitopes	NNS	epitope
on	IN	on
major	JJ	major
histocompatibility	NN	histocompatibility
complex	JJ	complex
(	-LRB-	(
MHC	NNP	MHC
)	-RRB-	)
molecules	NNS	molecule
.	.	.
</s>
<s type="decl">
At	IN	at
the	DT	the
same	JJ	same
time	NN	time
,	,	,
DCs	NNPS	DC
up-regulate	JJ	up-regulate
the	DT	the
maturation	NN	maturation
receptor	NN	receptor
,	,	,
release	VBP	release
potent	JJ	potent
cytokines	NNS	cytokine
,	,	,
and	CC	and
migrate	VB	migrate
into	IN	into
lymph	NN	lymph
nodes	NNS	node
to	TO	to
induce	VB	induce
systemic	JJ	systemic
immune	NN	immune
responses	NNS	response
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
standard	JJ	standard
DC-based	JJ	DC-based
vaccine	NN	vaccine
begins	VBZ	begin
with	IN	with
first	JJ	first
isolating	VBG	isolate
DCs	NNS	DC
from	IN	from
the	DT	the
patient	NN	patient
.	.	.
</s>
<s type="decl">
Then	RB	then
,	,	,
DCs	NNPS	DC
are	VBP	be
stimulated	VBN	stimulate
with	IN	with
the	DT	the
patient	NN	patient
’s	POS	&apos;s
tumor-associated	JJ	tumor-associated
antigen	NN	antigen
in	IN	in
vitro	FW	vitro
,	,	,
and	CC	and
the	DT	the
antigen-stimulated	JJ	antigen-stimulated
DCs	NNPS	DC
are	VBP	be
injected	VBN	inject
directly	RB	directly
back	RB	back
into	IN	into
the	DT	the
patient	NN	patient
to	TO	to
induce	VB	induce
the	DT	the
activation	NN	activation
of	IN	of
T	NNP	T
lymphocytes	NNS	lymphocyte
.	.	.
</s>
<s type="decl">
The	DT	the
patient	NN	patient
’s	POS	&apos;s
immune	JJ	immune
system	NN	system
will	MD	will
generate	VB	generate
the	DT	the
tumor-specific	JJ	tumor-specific
immune	NN	immune
response	NN	response
to	TO	to
destroy	VB	destroy
cancer	NN	cancer
cells	NNS	cell
and	CC	and
prevent	VB	prevent
cancer	NN	cancer
recurrence	NN	recurrence
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
several	JJ	several
drawbacks	NNS	drawback
restrict	VBP	restrict
the	DT	the
clinical	JJ	clinical
efficacy	NN	efficacy
of	IN	of
DC	NNP	DC
therapy	NN	therapy
.	.	.
</s>
<s type="decl">
First	RB	first
,	,	,
only	RB	only
a	DT	a
few	JJ	few
DCs	NNS	DC
actually	RB	actually
migrate	VBP	migrate
to	TO	to
the	DT	the
lymph	NN	lymph
nodes	NNS	node
and	CC	and
interact	VBP	interact
with	IN	with
T	NNP	T
lymphocytes	NNS	lymphocyte
,	,	,
with	IN	with
the	DT	the
result	NN	result
of	IN	of
a	DT	a
failure	NN	failure
to	TO	to
induce	VB	induce
antitumor	NN	antitumor
immune	NN	immune
responses	NNS	response
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
the	DT	the
in	IN	in
vitro	NN	vitro
culture	NN	culture
cannot	MD	can
generate	VB	generate
sufficiently	RB	sufficiently
powerful	JJ	powerful
DCs	NNS	DC
,	,	,
with	IN	with
the	DT	the
result	NN	result
of	IN	of
a	DT	a
weak	JJ	weak
immune	NN	immune
response	NN	response
and	CC	and
limited	VBN	limit
therapeutic	JJ	therapeutic
benefit	NN	benefit
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
it	PRP	it
is	VBZ	be
important	JJ	important
to	TO	to
establish	VB	establish
an	DT	an
in	IN	in
vitro	FW	vitro
culturing	NN	culture
system	NN	system
or	CC	or
an	DT	an
in	IN	in
vivo	FW	vivo
DC	NNP	DC
delivery	NN	delivery
system	NN	system
that	WDT	that
can	MD	can
more	RBR	more
reliably	RB	reliably
induce	VB	induce
the	DT	the
immune	JJ	immune
response	NN	response
and	CC	and
more	RBR	more
potently	RB	potently
deliver	VB	deliver
antitumor	NN	antitumor
immunity	NN	immunity
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
lymph	NN	lymph
nodes	NNS	node
are	VBP	be
extremely	RB	extremely
critical	JJ	critical
in	IN	in
responses	NNS	response
to	TO	to
pathogens	NNS	pathogen
or	CC	or
danger	NN	danger
signals	NNS	signal
,	,	,
and	CC	and
their	PRP$	their
major	JJ	major
functions	NNS	function
are	VBP	be
to	TO	to
filter	VB	filter
out	RP	out
deleterious	JJ	deleterious
substances	NNS	substance
by	IN	by
their	PRP$	their
unique	JJ	unique
mesh	NN	mesh
microstructure	NN	microstructure
,	,	,
to	TO	to
maintain	VB	maintain
matured	VBN	mature
immunocytes	NNS	immunocyte
,	,	,
and	CC	and
to	TO	to
initiate	VB	initiate
the	DT	the
antigen-specific	JJ	antigen-specific
adaptive	JJ	adaptive
immune	NN	immune
response	NN	response
.	.	.
</s>
<s type="sub">
The	DT	the
lymph	NN	lymph
nodes	NNS	node
might	MD	might
lose	VB	lose
their	PRP$	their
function	NN	function
because	IN	because
of	IN	of
cancer	NN	cancer
,	,	,
obstruction	NN	obstruction
,	,	,
or	CC	or
infection	NN	infection
;	:	;
in	IN	in
such	JJ	such
cases	NNS	case
,	,	,
surgical	JJ	surgical
resection	NN	resection
of	IN	of
lymph	NN	lymph
nodes	NNS	node
is	VBZ	be
usually	RB	usually
indicated	VBN	indicate
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
lymph	NN	lymph
node	NN	node
resection	NN	resection
often	RB	often
causes	VBZ	cause
a	DT	a
wide	JJ	wide
range	NN	range
of	IN	of
other	JJ	other
problems	NNS	problem
such	JJ	such
as	IN	as
increased	VBN	increase
infection	NN	infection
,	,	,
impaired	VBN	impaire
cancer	NN	cancer
surveillance	NN	surveillance
,	,	,
and	CC	and
lymphedema	NN	lymphedema
.	.	.
</s>
<s type="decl">
Consequently	RB	consequently
,	,	,
a	DT	a
promising	VBG	promising
technique	NN	technique
for	IN	for
functional	JJ	functional
lymph	NN	lymph
node	NN	node
restoration	NN	restoration
is	VBZ	be
urgently	RB	urgently
needed	VBN	need
.	.	.
</s>
</p>
<p>
<s type="decl">
Decellularization	NN	Decellularization
has	VBZ	have
emerged	VBN	emerge
as	IN	as
a	DT	a
process	NN	process
for	IN	for
producing	VBG	produce
a	DT	a
natural	JJ	natural
extracellular	JJ	extracellular
matrix	NN	matrix
(	-LRB-	(
ECM	NNP	ECM
)	-RRB-	)
,	,	,
which	WDT	which
preserves	VBZ	preserve
the	DT	the
intrinsic	JJ	intrinsic
biological	JJ	biological
cues	NNS	cue
and	CC	and
architectural	JJ	architectural
structure	NN	structure
of	IN	of
the	DT	the
original	JJ	original
tissue	NN	tissue
.	.	.
</s>
<s type="decl">
It	PRP	it
provides	VBZ	provide
a	DT	a
strategy	NN	strategy
by	IN	by
which	WDT	which
to	TO	to
fabricate	VB	fabricate
lymph	NN	lymph
node	NN	node
scaffolds	NNS	scaffold
on	IN	on
which	WDT	which
to	TO	to
grow	VB	grow
immune	JJ	immune
cells	NNS	cell
with	IN	with
immunological	JJ	immunological
function	NN	function
.	.	.
</s>
<s type="decl">
Previous	JJ	previous
studies	NNS	study
demonstrated	VBD	demonstrate
that	IN	that
spleen-derived	JJ	spleen-derive
decellularized	VBN	decellularize
ECM	JJ	ECM
or	CC	or
lymph	NN	lymph
node-associated	JJ	node-associated
decellularized	VBN	decellularize
ECM	NNP	ECM
can	MD	can
deliver	VB	deliver
immune	JJ	immune
cells	NNS	cell
and	CC	and
promote	VB	promote
the	DT	the
organization	NN	organization
of	IN	of
lymphoid-like	JJ	lymphoid-like
scaffolds	NNS	scaffold
;	:	;
however	RB	however
,	,	,
whether	IN	whether
these	DT	these
can	MD	can
induce	VB	induce
antigen-specific	JJ	antigen-specific
immunity	NN	immunity
or	CC	or
the	DT	the
antitumor	NN	antitumor
immune	NN	immune
response	NN	response
is	VBZ	be
still	RB	still
unknown	JJ	unknown
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
establish	VB	establish
a	DT	a
natural	JJ	natural
decellularized	JJ	decellularize
lymph	NN	lymph
node	NN	node
scaffold	NN	scaffold
(	-LRB-	(
dLN	NNP	dLN
)	-RRB-	)
,	,	,
with	IN	with
preserved	VBN	preserve
original	JJ	original
microstructure	NN	microstructure
and	CC	and
ECM	NNP	ECM
,	,	,
and	CC	and
to	TO	to
validate	VB	validate
the	DT	the
ability	NN	ability
of	IN	of
the	DT	the
dLN	NNP	dLN
to	TO	to
support	VB	support
DC	NNP	DC
proliferation	NN	proliferation
and	CC	and
maturation	NN	maturation
in	IN	in
vitro	FW	vitro
.	.	.
</s>
<s type="decl">
The	DT	the
study	NN	study
also	RB	also
aimed	VBD	aim
to	TO	to
verify	VB	verify
whether	IN	whether
a	DT	a
bone	NN	bo
marrow	NN	marrow
dendritic	FW	dendritic
cell	NN	cell
(	-LRB-	(
BMDC)-dLN	NNP	BMD4)-dLN
can	MD	can
activate	VB	activate
a	DT	a
specific	JJ	specific
antitumor	FW	antitumor
immune	NN	immune
response	NN	response
in	IN	in
vivo	FW	vivo
.	.	.
</s>
</p>
</text>
